Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Theratechnologies ( (TSE:TH) ) just unveiled an announcement.
On March 25, 2025, Theratechnologies announced that the U.S. FDA approved its supplemental Biologics License Application for the F8 formulation of tesamorelin, marketed under the name EGRIFTA WR™. This new formulation, which is bioequivalent to the original, offers a more convenient administration process requiring weekly reconstitution and a reduced injection volume compared to the current F4 formulation. The product, patent protected until 2033, will be manufactured in the U.S. and is expected to replace the existing EGRIFTA SV® formulation, potentially impacting the company’s market position by enhancing patient convenience and adherence.
More about Theratechnologies
Theratechnologies Inc. is a biopharmaceutical company based in Montreal, Quebec, Canada. The company focuses on developing and commercializing innovative therapies, primarily for patients with unmet medical needs in the field of endocrinology and HIV-related conditions. Its key product, tesamorelin, is used for reducing excess abdominal fat in adults with HIV who have lipodystrophy.
YTD Price Performance: -23.91%
Average Trading Volume: 1,067,694
Technical Sentiment Signal: Buy
Current Market Cap: $65.81M
See more data about TH stock on TipRanks’ Stock Analysis page.